pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,776 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1860Endpoints1445Fierce Biotech764BioSpace754BioPharma Dive548raps249onclive165fda recalls
therapy area
allOncology12884Rare Disease3330Immunology3020Cardiology2847Hematology2294Pulmonology2253Vaccines
  • Panelists say 2027 could be Europe’s breakout year for biotech investment
    Fierce Biotech hosted a panel during its London Life Sciences Week to debate whether Europe can boost its biopharma investment in 2027. The discussion came a day after venture capital firm Sofinno…
    Fierce Biotech · 1d agoPositive↗ source
  • Cardinal Health advises correction of Presource kits containing recalled BD Alaris infusion sets
    Cardinal Health has issued a correction notice for its Presource convenience kits that include BD Alaris pump infusion sets that were previously recalled. The FDA classifies this recall as the mos…
    fda medwatch · 1d agoCRLNegative↗ source
← prev
page 3 of 152
next →
119
fda medwatch114
globenewswire health73
fda press61
1853
Psychiatry & CNS1230
Ophthalmology1131
Endocrinology & Metabolism806
Pain790
Nephrology783
  • Flagship invests £100 million to launch AI-native biotech platform hub in the United Kingdom
    Flagship announced it will allocate £100 million to establish a new biotech creation outpost in the United Kingdom. The outpost will focus on building AI-native platform companies that aim to addr…
    STAT · 1d agoDealPositive↗ source
  • Flavored nicotine tablets launch, raising concerns over appeal to youth
    New flavored nicotine tablets that melt in the mouth have been introduced by tobacco companies in several markets. Products include Zyn Melts by Philip Morris International in the United Kingdom…
    STAT · 1d agoNegative↗ source
  • U.S. loses measles elimination status, sparking political criticism of vaccination response
    International health officials from the Pan American Health Organization announced that measles is no longer considered eliminated in the United States. The designation, first achieved in 2000, is…
    STAT · 1d agoRegulatoryNegative↗ source
  • Larbi Inc. recalls three lots of Yellow Dock Root over possible Salmonella contamination
    Larbi Inc. announced a recall of three lots of its Herb To Body Yellow Dock Root 4-oz product because it may be contaminated with Salmonella. The product was sold nationwide from January to Novemb…
    fda recalls · 20h agoCRLNegative↗ source
  • Democrats rally behind Medicare for More as Trump's chief of staff backs the plan
    Democrats are increasingly uniting around a new health care proposal called Medicare for More, which aims to broaden coverage beyond the existing system. The plan is drawing attention after the Wh…
    STAT · 1d agoNeutral↗ source
  • John Powers III named permanent director of NIH's National Institute of Allergy and Infectious Diseases
    NIH's National Institute of Allergy and Infectious Diseases (NIAID) has finally filled its top leadership vacancy that has persisted since 2025. The institute had been led in an acting capacity by…
    STAT · 1d agoNeutral↗ source
  • Biotech boards see more women, but CEO roles remain largely male-dominated
    Women now occupy roughly 29% of biotech board seats, a notable rise from about one‑fifth a few years ago, according to the latest Bedford Group Transearch report. Despite that progress, female CEO…
    BioSpace · 1d agoNegative↗ source
  • CMS releases new AI roadmap; highlights from HLTH conference
    The latest STAT Health Tech newsletter reports that the Centers for Medicare & Medicaid Services (CMS) has published a new artificial intelligence (AI) roadmap outlining its approach to AI integrat…
    STAT · 1d agoRegulatoryNeutral↗ source
  • RFK Jr. urges federal funding for faith-based addiction recovery centers, sparking expert concerns over medication access
    Health Secretary Robert F. Kennedy Jr. toured Sheepgate, a Christian addiction recovery center in Iowa, and said the model should receive federal funding. He highlighted the center as an example of…
    STAT · 1d agoRegulatoryNeutral↗ source
  • Zero-tolerance signs in hospitals may not curb staff violence, authors argue
    Hospitals across the United States now display signs telling patients and visitors that abusive language, disruptive conduct, or aggression will not be tolerated and may result in removal or police…
    STAT · 1d agoNegative↗ source
  • Fresh & Ready Foods expands recall to include additional Fresh to You sausage, egg & cheese biscuit sandwiches over Listeria risk
    Fresh & Ready Foods announced an expansion of its November 8 recall, now covering additional Fresh to You sausage, egg & cheese biscuit sandwiches made at its Longview, Texas facility. The move fo…
    fda recalls · 1d agoCRLNegative↗ source
  • CLINUVEL to cut up to 20% of staff and move headquarters to New York
    CLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…
    BioSpace · 1d agoLayoffsNegative↗ source
  • Lilly pens another deal, inking up to $5.9B oncology pact with Stipple
    A licensing pact with Stipple Bio was one of two announced by Eli Lilly on Monday, after the up to $1.5 billion buyout of blood cancer-focused Calytrix Bio.
    BioSpace · 1d ago↗ source
  • IQVIA report finds 90% of drugs launched 2016-2020 unlikely to recoup costs
    IQVIA analyzed 825 novel medicines launched in the United States between 1991 and 2020 and found that profitability has sharply declined over time. For drugs launched from 2016 to 2020, a positive…
    BioSpace · 2d agoNegative↗ source
  • J&J to acquire Ollin Biosciences for $2.2 billion to advance bispecific eye drug OLN324 against Roche’s Vabysmo
    Johnson & Johnson announced it will buy Ollin Biosciences for an upfront $2.2 billion, with additional regulatory and commercial milestones that could bring total payments to about $3.3 billion. O…
    Fierce Biotech · 2d agoDealPositive↗ source
  • FDA approves Roche's Wilserdly for advanced HR-positive, HER2-negative breast cancer with ESR1 mutation
    The U.S. Food and Drug Administration has granted approval to Roche's new oral breast cancer therapy, Wilserdly (giredestrant). The decision clears the way for the drug's launch in the United State…
    STAT · 1d agoApprovalPositive↗ source
  • Novo’s CagriSema shows over 20% weight loss at low doses in Phase 3 trial
    Novo Nordisk presented new Phase 3 data on its experimental obesity combo CagriSema at ObesityWeek 2026. The low‑dose arm (1 mg and 1.7 mg weekly) achieved average weight reductions of about 21% a…
    BioSpace · 2d agoPositive readoutPositive↗ source
  • Helus Pharma's modified psilocybin meets primary and secondary goals in phase 3 depression trial
    Helus Pharma reported that its oral, chemically modified psilocybin candidate, HLP003, was tested in a phase 3 study of 222 patients with major depressive disorder. Participants received a single 1…
    Fierce Biotech · 2d agoPositive readoutPositive↗ source
  • Eli Lilly acquires Calytrix Bio in $1.5 billion deal to add myelofibrosis antibody to its pipeline
    Eli Lilly announced a $1.5 billion acquisition of Massachusetts‑based Calytrix Bio, gaining access to the company’s biparatopic antibody aimed at mutant calreticulin‑driven essential thrombocythemi…
    Fierce Biotech · 2d agoDealPositive↗ source
  • Biogen signs $411 million deal with TrimTech to develop protein degraders for neurodegenerative diseases
    Biogen announced a collaboration with UK‑based TrimTech Therapeutics, valued at up to $411 million in biobucks, to create small‑molecule protein degraders aimed at neurodegenerative disorders. The…
    Fierce Biotech · 2d agoDealPositive↗ source
  • AriBio’s oral Alzheimer’s candidate shows significant benefit in monotherapy subgroup in phase 3 trial
    AriBio’s AR1001, an oral PDE5 inhibitor originally developed for erectile dysfunction, is being tested as a treatment for early Alzheimer’s disease. In the global phase 3 Polaris-AD trial, the dru…
    Fierce Biotech · 1d agoPositive readoutNeutral↗ source
  • Sellas vaccine shows 9-month overall survival gain in phase 3 AML trial
    Sellas Life Sciences reported results of a phase 3 trial of its peptide vaccine galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML). The study met its primary endpoint, showing a me…
    Fierce Biotech · 2d agoPositive readoutPositive↗ source
  • Helus Pharma’s Phase 3 trial shows strong depression benefit but safety concerns emerge
    Helus Pharma reported that its deuterated psilocin candidate HLP003 achieved the primary endpoint in a Phase 3 trial for major depressive disorder when added to patients' existing antidepressants.…
    BioSpace · 2d agoNegative readoutNegative↗ source